0001818331-26-000041
SEC filingRevenue grew 17% to $102.3M on 34% exome/genome volume growth; net loss widened to $63.3M due to $31.3M impairment and higher expenses.
For the three months ended March 31, 2026, GeneDx reported total revenue of $102.3 million, a 17% increase from $87.1 million in the same period of 2025. The growth was primarily driven by a 34% increase in whole exome and genome test volumes, which contributed to an 18% rise in diagnostic test revenue to $101.3 million. However, average reimbursement rates decreased by 5%, partially offsetting volume gains. Other revenue declined 30% to $1.0 million due to lower data deal activity, partially offset by contributions from the Fabric Genomics acquisition.
Gross profit increased 17% to $68.2 million, but gross margin contracted 40 basis points to 66.7% from 67.1% in the prior year, reflecting the impact of lower reimbursement rates and a shift in test mix. On a non-GAAP basis, adjusted gross margin remained nearly flat at 68.5% versus 68.6%.
Operating expenses surged, with research and development costs rising 57% to $19.8 million, driven by higher compensation and the inclusion of Fabric Genomics. Selling, general and administrative expenses jumped 48% to $74.6 million, reflecting investments in the commercial team and Fabric Genomics integration. The quarter also included a non-cash impairment loss of $31.3 million related to Fabric Genomics goodwill and intangible assets (goodwill $11.9M, developed technology $10.2M, customer relationships $5.0M, tradenames $4.2M). As a result, loss from operations widened to $57.5 million from $4.6 million. Net loss expanded to $63.3 million from $6.5 million, influenced also by a $6.6 million loss on extinguishment of long-term debt.
GeneDx operates as a single reporting segment focused on genomic diagnostic testing. The MD&A does not provide segment-level operating income breakdown. The primary revenue driver is diagnostic testing, which represented 99% of total revenue in Q1 2026. The acquisition of Fabric Genomics (closed Q2 2025) contributed to other revenue and increased operating costs but did not generate segment-level disclosure. The impairment of Fabric Genomics assets signals challenges in the acquired business.
Management emphasizes continued focus on growing exome and genome test volumes, expanding reimbursement coverage, and reducing cost per test through automation and scale. The Company believes its cash and marketable securities of $170.7 million provide sufficient liquidity for at least twelve months. No explicit revenue or earnings guidance was provided. Key strategic priorities include maintaining volume momentum, stabilizing reimbursement rates, and integrating Fabric Genomics while managing costs. The $31.3 million impairment highlights risks in acquired assets, but adjusted gross margin stability suggests core operational efficiency is being maintained.
As of March 31, 2026, GeneDx held $93.9M in cash and equivalents plus $76.8M in marketable securities, totaling $170.7M in liquid assets. Total debt stood at $96.7M (net of issuance costs), up from $52.7M at year-end 2025, driven by a new $100M Blackstone term loan (net proceeds $97.0M) used to repay $54.5M of prior indebtedness (Perceptive $50M principal plus $4.5M DECD loan). Shareholders' equity decreased to $254.1M from $308.2M, primarily due to a $63.3M net loss and $31.3M in impairment charges, partially offset by stock-based compensation ($9.0M) and equity issuances.
The company reported $33.5M in purchase commitments with software and equipment providers as of March 31, 2026, with annual breakdowns: $11.6M in 2026 (remaining), $12.9M in 2027, $4.1M in 2028, $3.9M in 2029, and $1.0M in 2030. Additionally, a new sublease for lab space in Gaithersburg, Maryland, adds $16.3M in minimum lease payments through 2033 (recognized as a right-of-use asset and lease liability). Legal contingencies include a $4.8M settlement agreement in principle for the Helo class action, subject to court approval, with $4.8M reserved in accounts payable.
No share buybacks or dividends were disclosed. Capital expenditures totaled $6.5M in Q1 2026 (6.3% of revenue), primarily for property, equipment, and internal-use software. Debt management was the key capital action: the company refinanced its debt structure by issuing $100M in new term loans (net $97M) and repaying $54.5M in prior loans, resulting in a net debt increase of $44.0M. The new loan carries a Term SOFR + 4.50% rate (1.50% floor) and matures in 2031, with a minimum liquidity covenant of $50M.
The company operates through one reportable segment, GeneDx, which generated $101.5M in revenue (99.3% of total) in Q1 2026, up 16.5% YoY. Adjusted gross profit for this segment was $69.9M. Two immaterial segments (Fabric Genomics and Legacy Sema4) contributed $0.8M combined. No geographic mix was disclosed. The CODM evaluates performance based on revenue and adjusted gross profit; segment asset information is not provided.
Operating cash flow (CFO) deteriorated sharply from a $10.2M inflow in Q1 2025 to a $32.4M outflow in Q1 2026, primarily driven by a net loss of $63.3M (vs. $6.5M loss in prior year). Non-cash charges (depreciation $6.8M, stock-based comp $9.0M, impairment $31.3M, loss on debt extinguishment $6.6M) partially offset the loss, but large working capital outflows—notably accounts payable and accrued expenses decreasing by $13.2M and other assets/liabilities absorbing $9.1M—weighed heavily.
Capex remained steady at $6.5M, indicating consistent investment in property, equipment, and software. Combined with negative CFO, free cash flow was deeply negative. No share repurchases or dividends were reported.
Anomalies include a $31.3M impairment loss and $6.6M loss on debt extinguishment, both non-recurring items that significantly impacted net income but not operating cash flow. The change in fair value of financial liabilities provided a $2.5M benefit. Overall, cash from operations was weak, and the company relied on financing activities ($38.6M, primarily debt proceeds) to offset the shortfall.